drugset / Trial / NCT05980416
Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
Phase 1
Terminated
88 enrolled
Elevation Oncology
CSPC Pharmaceutical Group Limited · collabEli Lilly and Company · collabGlaxoSmithKline · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.
Timeline
- Start
- 2023-08-10
- Primary completion
- 2025-05-07
- Completion
- 2025-06-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dostarlimab | Monoclonal antibody | — | — |
| Subject | EO-3021 | Other / unclassified | — | — |
| Subject | Ramucirumab | Monoclonal antibody | — | — |